A valid prescription requires a telehealth consultation with a prescriber. No medication is dispensed without clinical evaluation.
Semaglutide
GLP-1 Receptor Agonist
Compound Specifications
Semaglutide
GLP-1 Receptor Agonist
FDA-approved semaglutide products have been studied for effects on glycemic control, appetite signaling, and body weight. Compounded formulations are not FDA-approved.
This compounded semaglutide formulation is not FDA-approved and has not been reviewed by FDA for safety, effectiveness, or manufacturing quality. Individual results may vary.
Selectively activates GLP-1 receptors in the brain and gut, elevating postprandial insulin release while suppressing glucagon secretion. Slows gut motility to promote prolonged fullness.
Important Safety Information
Important Safety Information: Semaglutide therapy requires individualized medical evaluation. A licensed provider will review medical history, current medications, contraindications, potential adverse effects, and other clinical factors before prescribing. Seek urgent medical attention for severe or life-threatening symptoms.
Report suspected adverse reactions to your provider and to FDA MedWatch at 1-800-FDA-1088 or fda.gov/medwatch.
Clinical Evidence for Semaglutide
Clinical outcomes referenced on this page are based primarily on studies of FDA-approved semaglutide products and do not establish identical outcomes for compounded formulations.
Administered via weekly subcutaneous injection, titrated under clinical guidance to optimal patient response and tolerance.
Related Treatments & Resources
Frequently Asked Clinical Questions
How is Semaglutide shipped?
Shipped directly to your doorstep in insulated, temperature-controlled cold packs with tracking.
Where is this medication compounded?
Compounded and shipped from licensed U.S. compounding pharmacies pursuant to a patient-specific prescription.